Loading
Yanuki
KEYWORD TOPIC
uniQure Faces FDA Uncertainty for Huntington's Disease Drug AMT-130 | uniQure's AMT-130 Faces Regulatory Uncertainty for Huntington's Disease | uniQure Secures $175M Debt Facility to Advance Huntington's Disease Therapy | uniQure Faces FDA Uncertainty for Huntington's Disease Drug AMT-130 | uniQure's AMT-130 Faces Regulatory Uncertainty for Huntington's Disease | uniQure Secures $175M Debt Facility to Advance Huntington's Disease Therapy

Health / Gene Therapy

uniQure Faces FDA Uncertainty for Huntington's Disease Drug AMT-130

uniQure (QURE) faces regulatory uncertainty as the FDA questions the adequacy of existing data for its Huntington’s disease gene therapy, AMT-130, potentially delaying its approval timeline. This shift in the FDA's stance has significantly...

Uniqure’s FDA submission for its Huntington’s disease therapy thrown into question
uniQure Faces FDA Uncertainty for Huntington's Disease Drug AMT-130 Image via STAT
TOPIC qure stock

Health / Neurology

uniQure's AMT-130 Faces Regulatory Uncertainty for Huntington's Disease

uniQure (QURE) faces regulatory headwinds for its AMT-130 gene therapy targeting Huntington's Disease (HD). Recent feedback from the FDA suggests a shift in opinion regarding the adequacy of Phase I/II data for BLA submission, creating unce...

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

Finance / Biotech

uniQure Secures $175M Debt Facility to Advance Huntington's Disease Therapy

uniQure (QURE) has secured a $175 million non-dilutive senior secured term loan facility with Hercules Capital (HTGC) to bolster its financial flexibility. This funding aims to support the potential commercial launch of AMT-130, uniQure's g...

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding